The ANXA6 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human ANXA6 gene in the HT29 colorectal adenocarcinoma cell line. This gene-edited product enables loss-of-function studies of Annexin A6, a calcium-dependent membrane-binding protein involved in multiple signaling and trafficking pathways. The polyclonal nature of the knockout pool provides a heterogeneous genetic background that mimics natural variation, making it suitable for pooled functional screens and model generation without clonal selection bias.
The HT29 host cell line is a well-established human colorectal adenocarcinoma model originally derived from a primary tumor. These cells carry an APC mutation and are extensively utilized as an intestinal epithelial model for studying colorectal cancer biology, drug responses, and signal transduction. HT29 cells retain epithelial characteristics and are capable of forming polarized monolayers, making them relevant for both proliferative and differentiation-dependent studies.
Annexin A6 functions as a calcium-sensitive scaffold that associates with negatively charged phospholipids and modulates membrane microdomain organization. It interacts with S100A10 and S100A11 proteins, linking to actin cytoskeleton dynamics and membrane trafficking. In signaling, ANXA6 acts as a negative regulator of EGFR-mediated signal transduction by promoting receptor internalization and limiting downstream activation of RAS-RAF-MEK-ERK (MAPK1/3) and AKT pathways. Additionally, ANXA6 participates in cholesterol homeostasis by facilitating cholesterol efflux from endosomes to the plasma membrane, influencing lipid raft composition and signal compartmentalization. Its expression is regulated by EGF stimulation, intracellular calcium levels, and NF-kB transcriptional activity.
In the HT29 colorectal cancer background, disruption of ANXA6 is expected to perturb EGFR signaling dynamics and cholesterol distribution, directly impacting tumor cell behavior. Enhanced EGFR-MAPK signaling upon ANXA6 loss can promote uncontrolled proliferation and migration, while altered cholesterol trafficking may affect membrane receptor clustering and drug responsiveness. This knockout model is valuable for dissecting Annexin A6’s role in colorectal cancer progression, including its potential involvement in cetuximab resistance mechanisms and metabolic reprogramming. Moreover, the interplay between APC mutation-driven Wnt pathway activation and ANXA6-mediated control of EGFR and cholesterol pathways provides a unique system to study cooperative oncogenic signaling networks.
This ANXA6 knockout cell pool is ideally suited for investigating colorectal cancer proliferation and drug resistance mechanisms. Researchers can employ Western blotting and RT-qPCR to validate loss of ANXA6 expression and monitor changes in EGFR, MAPK1/3 (ERK), and AKT phosphorylation. Cell proliferation assays (MTT or CCK-8) and transwell migration/invasion assays allow functional interrogation of Annexin A6’s role in tumor cell dynamics. Drug sensitivity profiling, including IC50 determinations for chemotherapeutics or targeted agents, can reveal ANXA6-dependent vulnerabilities. Cholesterol efflux assays and co-immunoprecipitation studies with S100A10 and cholesterol provide mechanistic insights into membrane trafficking and signaling cross-talk. Immunofluorescence enables visualization of Annexin A6 localization changes and cytoskeletal reorganization. For further information or technical support, please contact Ascent Research.
